Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'".
作者信息
Okubo Yukari, Kobayashi Satomi, Murakami Masamoto, Sano Shigetoshi, Kikuta Natsuko, Ouchi Yoshiumi, Terui Tadashi
机构信息
Department of Dermatology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Department of Dermatology, Seibo International Catholic Hospital, 2-5-1 Nakaochiai, Shinjuku-ku, Tokyo, 161-8521, Japan.
出版信息
Am J Clin Dermatol. 2024 Nov;25(6):1025-1027. doi: 10.1007/s40257-024-00896-7. Epub 2024 Oct 15.
Abstract
摘要
相似文献
1
Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'".作者对Wang等人《关于“抗白细胞介素-17受体A单克隆抗体布罗达单抗治疗掌跖脓疱病的疗效和安全性：一项随机临床试验的16周结果”的评论》的回复
Am J Clin Dermatol. 2024 Nov;25(6):1025-1027. doi: 10.1007/s40257-024-00896-7. Epub 2024 Oct 15.
2
Comment on "Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial".关于“抗白细胞介素-17受体A单克隆抗体布罗达单抗治疗掌跖脓疱病的疗效和安全性：一项随机临床试验的16周结果”的评论
Am J Clin Dermatol. 2024 Nov;25(6):1023-1024. doi: 10.1007/s40257-024-00895-8. Epub 2024 Oct 15.
3
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.白介素-17 受体 A 单克隆抗体布罗达卢单抗治疗掌跖脓疱病的疗效和安全性：一项随机临床试验的 16 周结果。
Am J Clin Dermatol. 2024 Sep;25(5):837-847. doi: 10.1007/s40257-024-00876-x. Epub 2024 Jul 2.
4
Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.靶向白细胞介素-17 受体的单克隆抗体治疗银屑病：疗效评价。
Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.
5
Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'.关于“抗IL17RA单克隆抗体布罗达单抗治疗中轴型脊柱关节炎患者的疗效和安全性：一项随机、安慰剂对照的3期试验的16周结果”的通信
Ann Rheum Dis. 2023 Jul;82(7):e168. doi: 10.1136/annrheumdis-2021-220759. Epub 2021 Jun 25.
6
Interventions for chronic palmoplantar pustulosis.慢性掌跖脓疱病的干预措施。
Cochrane Database Syst Rev. 2020 Jan 20;1(1):CD011628. doi: 10.1002/14651858.CD011628.pub2.
7
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.司妥昔单抗治疗中重度掌跖脓疱病的疗效与安全性：一项多中心、双盲、随机、安慰剂对照、IIb期剂量探索研究
Dermatol Ther (Heidelb). 2023 Oct;13(10):2279-2297. doi: 10.1007/s13555-023-01002-1. Epub 2023 Sep 20.
8
Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.白介素-17 受体 A 阻断剂布罗利尤单抗治疗掌跖脓疱性银屑病：四例报告。
J Dermatol. 2019 May;46(5):426-430. doi: 10.1111/1346-8138.14815. Epub 2019 Feb 20.
9
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.布罗达单抗，一种治疗日本中重度斑块状银屑病患者的人抗白细胞介素-17受体抗体：一项II期随机对照研究的疗效和安全性结果。
J Dermatol Sci. 2016 Jan;81(1):44-52. doi: 10.1016/j.jdermsci.2015.10.009. Epub 2015 Oct 24.
10
Guselkumab for the treatment of palmoplantar pustulosis.古塞库单抗治疗掌跖脓疱病。
Expert Opin Biol Ther. 2020 Aug;20(8):841-852. doi: 10.1080/14712598.2020.1760244. Epub 2020 May 12.
引用本文的文献
1
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system.一项基于美国食品药品监督管理局不良事件报告系统的关于布罗达单抗的真实世界药物警戒研究。
Sci Rep. 2025 Jan 17;15(1):2346. doi: 10.1038/s41598-025-86976-y.
本文引用的文献
1
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.白介素-17 受体 A 单克隆抗体布罗达卢单抗治疗掌跖脓疱病的疗效和安全性：一项随机临床试验的 16 周结果。
Am J Clin Dermatol. 2024 Sep;25(5):837-847. doi: 10.1007/s40257-024-00876-x. Epub 2024 Jul 2.
2
A genome-wide meta-analysis of palmoplantar pustulosis implicates T2 responses and cigarette smoking in disease pathogenesis.全基因组荟萃分析提示掌跖脓疱病与 T2 反应和吸烟有关。
J Allergy Clin Immunol. 2024 Sep;154(3):657-665.e9. doi: 10.1016/j.jaci.2024.05.015. Epub 2024 May 28.
3
Risankizumab: Mechanism of action, clinical and translational science.里莎珠单抗：作用机制、临床与转化科学。
Clin Transl Sci. 2024 Jan;17(1):e13706. doi: 10.1111/cts.13706.
4
Paradoxical skin lesions induced by IL-17 inhibitors in SAPHO syndrome.IL-17抑制剂在SAPHO综合征中诱发的矛盾性皮肤病变。
J Dermatolog Treat. 2024 Dec;35(1):2295239. doi: 10.1080/09546634.2023.2295239. Epub 2023 Dec 28.
5
Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab.用比美克珠单抗治疗严重掌跖脓疱性银屑病。
JAMA Dermatol. 2024 Feb 1;160(2):199-203. doi: 10.1001/jamadermatol.2023.5051.
6
Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases.与用于炎症性皮肤病的靶向生物制剂相关的反常反应的发病机制。
Biomedicines. 2022 Jun 23;10(7):1485. doi: 10.3390/biomedicines10071485.
7
Single-cell analysis implicates T17-to-T2 cell plasticity in the pathogenesis of palmoplantar pustulosis.单细胞分析表明T17至T2细胞可塑性与掌跖脓疱病的发病机制有关。
J Allergy Clin Immunol. 2022 Oct;150(4):882-893. doi: 10.1016/j.jaci.2022.04.027. Epub 2022 May 12.
8
Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.在一项随机3期研究中，古塞库单抗治疗掌跖脓疱病患者1.5年的持续疗效和安全性。
J Dermatol. 2021 Dec;48(12):1838-1853. doi: 10.1111/1346-8138.16132. Epub 2021 Aug 28.
9
The Role of Th17-Related Cytokines in Atopic Dermatitis.Th17 相关细胞因子在特应性皮炎中的作用。
Int J Mol Sci. 2020 Feb 15;21(4):1314. doi: 10.3390/ijms21041314.
10
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.司库奇尤单抗治疗中重度掌跖脓疱型银屑病：2PRECISE 研究结果。
J Am Acad Dermatol. 2019 May;80(5):1344-1352. doi: 10.1016/j.jaad.2019.01.066. Epub 2019 Feb 1.
Zotero 插件